强化与标准血压控制的成本效益分析
基于SPRINT试验数据,采用微观模拟模型评估强化收缩压控制(目标<120 mm Hg)与标准控制(目标<140 mm Hg)的终身健康获益与医疗费用。强化控制组平均QALY增加0.27,每获得1个QALY的增量成本在疗效5年后减弱时为约47,000美元,疗效终身持续时为约28,000美元。多数模拟结果显示强化治疗具有成本效益。
要点
- 强化收缩压控制较标准控制平均增加0.27个QALY。
- 若5年后依从性和疗效减弱,每QALY增量成本约47,000美元。
- 若疗效终身持续,每QALY增量成本约28,000美元。
核心结论
- 强化收缩压控制可预防心血管疾病事件并延长寿命,且每QALY增量成本低于常用支付意愿阈值,无论获益在5年后减弱还是终身持续。
研究设计与样本
- 微观模拟模型研究,将SPRINT试验的治疗效应和全国来源的医疗费用应用于 hypothetical 符合SPRINT条件的成人队列。
主要发现
- 强化控制组平均QALY较标准控制组高0.27。
- 若5年后依从性和治疗效应减弱,每获得1个QALY增量成本约47,000美元。
- 若治疗效应终身持续,每获得1个QALY增量成本约28,000美元。
- 多数模拟结果显示强化治疗具有成本效益:在每QALY支付意愿阈值50,000美元下,51%至79%的模拟低于阈值;在100,000美元阈值下,76%至93%的模拟低于阈值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the Systolic Blood Pressure Intervention Trial (SPRINT), adults at high risk for cardiovascular disease who received intensive systolic blood-pressure control (target, <120 mm Hg) had significantly lower rates of death and cardiovascular disease events than did those who received standard control (target, <140 mm Hg). On the basis of these data, we wanted to determine the lifetime health benefits and health care costs associated with intensive control versus standard control. METHODS: We used a microsimulation model to apply SPRINT treatment effects and health care costs from national sources to a hypothetical cohort of SPRINT-eligible adults. The model projected lifetime costs of treatment and monitoring in patients with hypertension, cardiovascular disease events and subsequent treatment costs, treatment-related risks of serious adverse events and subsequent costs, and quality-adjusted life-years (QALYs) for intensive control versus standard control of systolic blood pressure. RESULTS: We determined that the mean number of QALYs would be 0.27 higher among patients who received intensive control than among those who received standard control and would cost approximately $47,000 more per QALY gained if there were a reduction in adherence and treatment effects after 5 years; the cost would be approximately $28,000 more per QALY gained if the treatment effects persisted for the remaining lifetime of the patient. Most simulation results indicated that intensive treatment would be cost-effective (51 to 79% below the willingness-to-pay threshold of $50,000 per QALY and 76 to 93% below the threshold of $100,000 per QALY), regardless of whether treatment effects were reduced after 5 years or persisted for the remaining lifetime. CONCLUSIONS: In this simulation study, intensive systolic blood-pressure control prevented cardiovascular disease events and prolonged life and did so at levels below common willingness-to-pay thresholds per QALY, regardless of whether benefits were reduced after 5 years or persisted for the patient's remaining lifetime. (Funded by the National Heart, Lung, and Blood Institute and others; SPRINT ClinicalTrials.gov number, NCT01206062 .).
引用
- Bress AP, Bellows BK, King JB, et al. Cost-Effectiveness of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2017. PMID: 28834469. doi:10.1056/NEJMsa1616035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。